Document Detail


Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
MedLine Citation:
PMID:  20824828     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Low molecular weight heparins (LMWHs) have been shown to be effective and safe in preventing venous thromboembolism (VTE). They may also be effective for the initial treatment of VTE. This is an update of a Cochrane review first published in 1999 and previously updated in 2004.
OBJECTIVES: To determine the effect of LMWH compared with unfractionated heparin (UFH) for the initial treatment of VTE.
SEARCH STRATEGY: Trials were identified by searching the Cochrane Peripheral Vascular Diseases Group Specialised Register and CENTRAL (The Cochrane Library). Colleagues and pharmaceutical companies were contacted for additional information.
SELECTION CRITERIA: Randomised controlled trials comparing fixed dose subcutaneous LMWH with adjusted dose intravenous or subcutaneous UFH in people with VTE.
DATA COLLECTION AND ANALYSIS: Two review authors assessed trials for inclusion and quality, and extracted data independently.
MAIN RESULTS: Twenty-three studies were included (n = 9587). Thrombotic complications occurred in 3.6% of participants treated with LMWH compared with 5.3% treated with UFH (odds ratio (OR) 0.70; 95% confidence interval (CI) 0.57 to 0.85). Thrombus size was reduced in 53% of participants treated with LMWH and 45% treated with UFH (OR 0.69; 95% CI 0.59 to 0.81). Major haemorrhages occurred in 1.1% of participants treated with LMWH compared with 1.9% treated with UFH (OR 0.58; 95% CI 0.40 to 0.83). In 19 trials, 4.3% of participants treated with LMWH died compared with 5.8% of participants treated with UFH (OR 0.77; 95% CI 0.63 to 0.93).Nine studies (n = 4451) examined proximal thrombosis, 2192 participants were treated with LMWH and 2259 with UFH. Subgroup analysis showed statistically significant reductions favouring LMWH in thrombotic complications and major haemorrhage. By end of follow up, 80 (3.6%) participants treated with LMWH had thrombotic complications compared with 143 (6.3%) treated with UFH (OR 0.57; 95% CI 0.44 to 0.75). Major haemorrhages occurred in 18 (1.0%) participants treated with LMWH compared with 37 (2.1%) treated with UFH (OR 0.50; 95% CI 0.29 to 0.85). Nine studies showed a statistically significant reduction in mortality favouring LMWH. By the end of follow up, 3.3% (70/2094) of participants treated with LMWH had died and 5.3% (110/2063) treated with UFH.
AUTHORS' CONCLUSIONS: Fixed dose LMWH is more effective and safer than adjusted dose UFH for the initial treatment of VTE. Compared to UFH, LMWH significantly reduced the incidence of thrombotic complications, the occurrence of major haemorrhage during initial treatment and overall mortality at follow up.
Authors:
Petra Mg Erkens; Martin H Prins
Related Documents :
20226548 - Argatroban for elective percutaneous coronary intervention: the arg-e04 multi-center st...
433668 - Rapid thrombolysis and preservation of valvular venous function in high deep vein throm...
6662638 - Low-dose heparin prophylaxis and postoperative wound hematoma.
20129998 - D-dimer level as a risk factor for postoperative venous thromboembolism in japanese wom...
3358568 - Treatment of condyloma acuminatum with three different interferons administered intrale...
8402108 - Abdominal aortic aneurysm in the elderly.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2010-09-08
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-08     Completed Date:  2010-10-18     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD001100     Citation Subset:  IM    
Affiliation:
Department of General Practice, University of Maastricht, Debyeplein 1, Maastricht, Netherlands, 6229 HA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Hemorrhage / chemically induced
Heparin / administration & dosage,  adverse effects
Heparin, Low-Molecular-Weight / administration & dosage*,  adverse effects
Humans
Injections, Subcutaneous
Pulmonary Embolism / drug therapy*,  mortality
Randomized Controlled Trials as Topic
Venous Thrombosis / drug therapy*,  mortality
Chemical
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight; 9005-49-6/Heparin
Comments/Corrections
Update Of:
Cochrane Database Syst Rev. 2004;(4):CD001100   [PMID:  15495007 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Short-course antibiotics for acute otitis media.
Next Document:  Surgery for faecal incontinence in adults.